Baixinan announced on the Hong Kong Stock Exchange that the company recently signed a strategic cooperation agreement with Shenqi Medical to jointly promote the commercialization and clinical application of the Bioheart® bioabsorbable rapamycin-eluting coronary stent system.

Zhitongcaijing · 2d ago
Baixinan announced on the Hong Kong Stock Exchange that the company recently signed a strategic cooperation agreement with Shenqi Medical to jointly promote the commercialization and clinical application of the Bioheart® bioabsorbable rapamycin-eluting coronary stent system.